Tumor Targeting Agents for Neutron Capture Therapy
The development of compounds for use as delivery agents in the treatment of cancer by neutron capture therapy has largely focused on the use of boron-10 even though there are other nuclides having higher capture cross section values for thermal neutrons. The major reasons are: (1) it is nonradioactive and comprises approximately 20% of naturally occurring boron; (2) boron-10 enriched materials are readily available commercially; (3) the products of the fission reaction are largely high LET recoiling 7Li and 4He (alpha) nuclei; (4) the pathlength of these particles is such that they are confined to a radius approximating the diameter of a single cell; and (5) the chemistry of boron is such that it may be incorporated into a multitude of different stable chemical structures.
KeywordsBoron Atom Boron Neutron Capture Therapy Relative Biological Effectiveness Brookhaven National Laboratory Boron Compound
Unable to display preview. Download preview PDF.
- 3.Y. Hayashi, H. Furukawa, Y. Kawano, M. Matsuwa, A. Harihara, S. Aratri, Y. Muraoka, Y. Maeda, T. Yamashita, and M. Muto, “Toxicity of Sodium Monomercaptoundecahydro-closo-dodecaborate by Single Intravenous Inspection,” Research Report from the Shionogi Research Laboratory (Privileged Communication).Google Scholar
- 4.H. Hatanaka, K. Amano, H. Kanemitsu, I. Ikeuchi, and T. Yoshizki, “Boron Uptake by Human Brain Tumors and Quality Control of Boron Compounds,” in Boron-Neutron Capture Therapy for Tumors, H. Hatanaka, ed., Chapter V, Nishimura Co., Ltd., Niigata, Japan, p. 77 (1986).Google Scholar
- 6.H. Hatanaka and Y. Urano, “Eighteen Autopsy Cases of Malignant Brain Tumors Treated by Boron-Neutron Capture Therapy between 1968 and 1985,” in Boron-Neutron Capture Therapy for Tumors, H. Hatanaka, ed., Chapter XXVI, Nishimura Co., Ltd., Niigata, Japan, p. 381 (1986).Google Scholar
- 11.Y. Mishima, Pigment Cell, 1: 215 (1973).Google Scholar
- 15.W. Tjarks and D. Gabel, “Synthesis of Boronated Thioureas for Neutron Capture Therapy,” Third Int. Symp. on Neutron Capture Therapy, Bremen, FRG, 31 May - 3 June 1988.Google Scholar
- 17.F. Alain, B. V. Bapat, A. H. Soloway, R. F. Barth, N. Mafune, and D. M. Adams, “Boronated Compounds for Neutron Capture Therapy,” Strahlenther. Onkol., 165 (2/3): 121 (1989).Google Scholar
- 18.S. B. Kahl. Kahl, “Present Developments in the Synthesis and Isolation of Atropisomers of Porphyrinic Carburanyl Anilides,” Second Int. Symp. on Neutron Capture Therapy, Tokyo, 1985, H. Hatanaka, ed., Nishimura Co., Ltd., Niigata, Japan (1986).Google Scholar
- 19.R. F. Schinazi, B. H. Laster; R. G. Fairchild, and W. H. Prusoff, “Synthesis and Biological Activity for a Boron-Containing Pyrimidine Nucleoside,” First Int. Symp. on Neutron Capture Therapy, Cambridge, MA, 1983, R. G. Fairchild and G. L. Brownell, eds., Brookhaven National Laboratory, BNL-51730, p.260 (1984).Google Scholar
- 20.R. F. Barth, N. Mafune, F. Alam, D. M. Adams, A. H. Soloway, G. E. Makroglu, O. A. Oredipe, T. E. Blue, and Z. Steplewski, “Conjugation, Purification and Characterization of Boronated Monoclonal Antibodies for Use in Neutron Capture Therapy,” Strahlenther. Onkol., 165 (2/3): 142 (1989).PubMedGoogle Scholar
- 23.F. Alam, A. H. Soloway, R. F. Barth, and D. M. Adams, “Chemoradiotherapy of Cancer: Boronated Antibodies and Boron Containing Derivatives of Promazine for Neutron Capture Therapy,” in Neutron Capture Therapy, H. Hatanaka, ed., Nishimura Co., Ltd., Niigata, Japan, p. 8 (1986).Google Scholar
- 24.S. B. Kahl, First Boron USA Workshop, Dallas, Texas, 10–13 April 1988.Google Scholar